Takeda’s ACTOS reduces heart attack risk for diabetics

A new drug from Takeda has been found to reduce the risk of having a heart attack for type 2 diabetics.

Recent results from the PROactive study found that ACTOS reduced the risk of attack by 28 per cent amongst those with the condition. It also found that the drug reduced the chance of developing acute coronary syndrome (ACS) by 37 per cent.

The study looked at the ability of the glucose reducing agent to help reduce total mortality from macrovascular complications. The results showed that the total risk from strokes, heart attacks and death were reduced by 16 per cent.

“Takeda is breaking new ground with the PROactive Study. Never before have this many high-risk people with type 2 diabetes and cardiovascular disease been studied,” Robert Spanheimer, Takeda’s medical director for diabetes and metabolism.

“These results are very meaningful for the diabetes community, especially when you consider that people with type 2 diabetes are more likely than those without diabetes to die from a heart attack and to have a second event,” he added.

The study looked at 5,238 patients who had type 2 diabetes and macrovascular disease.

© Adfero Ltd